DGDA, a local sequence of the kringle 2 domain, is a functional motif of the tissue-type plasminogen activator's antiangiogenic kringle domain

Biochemical and Biophysical Research Communications

Volumn 391, Issue 1, 2010, Pages 166-169

  Kim, Hyun Kyung ^a   Joe, Young Ae ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Angiogenesis inhibitor; DGDA; DGEA; Integrin 2 1; Kringle domain; Migration

Indexed keywords

ANGIOGENESIS INHIBITOR; ARGINYLGLYCYLASPARTIC ACID; ASPARTYLGLYCYLALANYLGLUTAMIC ACID; ASPARTYLGLYCYLASPARTYLALANINE; ASPARTYLGLYCYLGLUTAMYLALANINE; COLLAGEN TYPE 1; EPITOPE; MATRIGEL; PEPTIDE DERIVATIVE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMINO ACID SEQUENCE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL ADHESION; CELL ASSAY; CELL DIFFERENTIATION; CELL MIGRATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; ENDOTHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMOBILIZATION; KRINGLE DOMAIN; PRIORITY JOURNAL; PROTEIN MOTIF; STEM CELL; UMBILICAL VEIN;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; CELL ADHESION; CELL DIFFERENTIATION; CELL MOVEMENT; COLLAGEN; EPITHELIAL CELLS; HUMANS; KRINGLES; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGOPEPTIDES; TISSUE PLASMINOGEN ACTIVATOR;

EID: 72949093129     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.11.025     Document Type: Article

References (29)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
2. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 175 (1972) 409-416
3. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., and Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 (1994) 315-328
4. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. Endostat: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
5. Nyberg P., Xie L., and Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res. 65 (2005) 3967-3979
6. Kim H.K., Oh D.S., Lee S.B., Ha J.M., and Joe Y.A. Antimigratory effect of TK1-2 is mediated in part by interfering with integrin alpha2beta1. Mol. Cancer Ther. 7 (2008) 2133-2141
7. Kang B.H., Shim B.S., Lee S.Y., Lee S.K., Hong Y.K., and Joe Y.A. Potent anti-tumor and prolonged survival effects of E. coli-derived non-glycosylated kringle domain of tissue-type plasminogen activator. Int. J. Oncol. 28 (2006) 361-367
8. Shim B.S., Kang B.H., Hong Y.K., Kim H.K., Lee I.H., Lee S.Y., Lee Y.J., Lee S.K., and Joe Y.A. The kringle domain of tissue-type plasminogen activator inhibits in vivo tumor growth. Biochem. Biophys. Res. Commun. 327 (2005) 1155-1162
9. Kim H.K., Lee S.Y., Oh H.K., Kang B.H., Ku H.J., Lee Y., Shin J.Y., Hong Y.K., and Joe Y.A. Inhibition of endothelial cell proliferation by the recombinant kringle domain of tissue-type plasminogen activator. Biochem. Biophys. Res. Commun. 304 (2003) 740-746
10. Oh H.K., Ha J.M., Eunjo O., Lee B.H., Lee S.K., Shim B.S., Hong Y.K., and Joe Y.A. Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2. Cancer Res. 67 (2007) 4851-4859
11. Carroll V.A., Nikitenko L.L., Bicknell R., and Harris A.L. Antiangiogenic activity of a domain deletion mutant of tissue plasminogen activator containing kringle 2. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 736-741
12. Senger D.R., Claffey K.P., Benes J.E., Perruzzi C.A., Sergiou A.P., and Detmar M. Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc. Natl. Acad. Sci. USA 94 (1997) 13612-13617
13. Senger D.R., Perruzzi C.A., Streit M., Koteliansky V.E., de Fougerolles A.R., and Detmar M. The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration and tumor angiogenesis. Am. J. Pathol. 160 (2002) 195-204
14. San Antonio J.D., Zoeller J.J., Habursky K., Turner K., Pimtong W., Burrows M., Choi S., Basra S., Bennett J.S., DeGrado W.F., and Iozzo R.V. A key role for the integrin alpha2beta1 in experimental and developmental angiogenesis. Am. J. Pathol. 175 (2009) 1338-1347
15. Staatz W.D., Fok K.F., Zutter M.M., Adams S.P., Rodriguez B.A., and Santoro S.A. Identification of a tetrapeptide recognition sequence for the alpha 2 beta 1 integrin in collagen. J. Biol. Chem. 266 (1991) 7363-7367
16. Luzak B., Golanski J., Rozalski M., Bonclerand M.A., and Watala C. Inhibition of collagen-induced platelet reactivity by DGEA peptide. Acta Biochim. Pol. 50 (2003) 1119-1128
17. De Falco E., Porcelli D., Torella A.R., Straino S., Iachininoto M.G., Orlandi A., Truffa S., Biglioli P., Napolitano M., Capogrossi M.C., and Pesce M. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 104 (2004) 3472-3482
18. Tan D.C., Kini R.M., Jois S.D., Lim D.K., Xin L., and Ge R. A small peptide derived from Flt-1 (VEGFR-1) functions as an angiogenic inhibitor. FEBS Lett. 494 (2001) 150-156
19. Asahara T., Takahashi T., Masuda H., Kalka C., Chen D., Iwaguro H., Inai Y., Silver M., and Isner J.M. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18 (1999) 3964-3972
20. Wijelath E.S., Rahman S., Murray J., Patel Y., Savidge G., and Sobel M. Fibronectin promotes VEGF-induced CD34 cell differentiation into endothelial cells. J. Vasc. Surg. 39 (2004) 655-660
21. Ruegg C., and Mariotti A. Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis. Cell. Mol. Life Sci. 60 (2003) 1135-1157
22. Kim J.S., and Moon A. Fibronectin induces pro-MMP-2 activation and enhances invasion in H-Ras transformed human breast epithelial cells. Biomol. Ther. 17 (2009) 288-292
23. Morrison J.C. Integrins in the optic nerve head: potential roles in glaucomatous optic neuropathy (an American Ophthalmological Society thesis). Trans. Am. Ophthalmol. Soc. 104 (2006) 453-477
24. Kirchhofer D., Languino L.R., Ruoslahti E., and Pierschbacher M.D. Alpha 2 beta 1 integrins from different cell types show different binding specificities. J. Biol. Chem. 265 (1990) 615-618
25. Hennessy K.M., Pollot B.E., Clem W.C., Phipps M.C., Sawyer A.A., Culpepper B.K., and Bellis S.L. The effect of collagen I mimetic peptides on mesenchymal stem cell adhesion and differentiation, and on bone formation at hydroxyapatite surfaces. Biomaterials 30 (2009) 1898-1909
26. Sulochana K.N., Fan H., Jois S., Subramanian V., Sun F., Kini R.M., and Ge R. Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis. J. Biol. Chem. 280 (2005) 27935-27948
27. Fairlie D.P., West M.L., and Wong A.K. Towards protein surface mimetics. Curr. Med. Chem. 5 (1998) 29-62
28. Griffioen A.W., van der Schaft D.W., Barendsz-Janson A.F., Cox A., Struijker Boudier H.A., Hillen H.F., and Mayo K.H. Anginex, a designed peptide that inhibits angiogenesis. Biochem. J. 354 (2001) 233-242
29. Maeshima Y., Yerramalla U.L., Dhanabal M., Holthaus K.A., Barbashov S., Kharbanda S., Reimer C., Manfredi M., Dickerson W.M., and Kalluri R. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. J. Biol. Chem. 276 (2001) 31959-31968